Antibody fragment therapy articles from across Nature Portfolio

Single domain antibodies block tau entry into neurons, a key step in tau propagation in the brain in Alzheimer’s disease. They prevent tau from binding to surface receptors by competition. The most effective, VHH H3-2, has a unique binding mode to tau.

A SARS-CoV-2 antibody, NT-108, exhibits potent therapeutic effects in vivo. Cryo-EM structure of the spike complexed with single-chain Fv of NT108 reveals its neutralizing mechanism, providing insight into antibody therapeutic design.

CD388 is a first-in-class antiviral drug–Fc conjugate engineered for extended half-life that demonstrates potent prophylactic and therapeutic efficacy against lethal influenza A and B challenge in mice.

In this work, a mirror-image protein binder derived from a monobody targeting MCP-1 is generated via in vitro display technology and chemical synthesis. It exhibits pharmaceutically promising properties, including protease resistance, negligible immunogenicity, and a potent inhibitory effect on cell migration.

Synthesis and screening of a small library of antibody fragments yields promising hits.